3 assets in Chronic Hepatitis C Virus Infection

Therapeutic assets addressing Chronic Hepatitis C Virus Infection, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Epclusa Chronic Hepatitis C Virus Infection	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	P4	BB (65)
Bemnifosbuvir Chronic Hepatitis C Virus Infection	Atea Pharmaceuticals, Inc.	P2	B (57)
Ruzasvir Chronic Hepatitis C Virus Infection	Atea Pharmaceuticals, Inc.	P2	B (57)